Search - tctmd.com

Displaying 1 - 20 of 22

Sort: Relevancy | Date

News Daily News

Year in Review: Physicians Pick the Biggest News of 2017, in Interventional Cardiology and Beyond

Shelley Wood

December 26, 2017

News Conference News AHA 2017

Missed by Risk Calculators, Few Young MI Patients Were Previously on Statins

Caitlin E. Cox

November 14, 2017

News Opinion Editor's Corner

TCTMD’s Top 10 Most Popular Stories for October 2017

Shelley Wood

October 29, 2017

News Daily News

Lp(a) Not Associated With Adverse Cardiovascular Events in ACS Patients

Michael O'Riordan

October 26, 2017

News Daily News

Colchicine Stabilizes Plaque in ACS Patients, Imaging Study Suggests

Michael O'Riordan

October 20, 2017

News Opinion Editor's Corner

TCTMD’s Top 10 Most Popular Stories for August 2017

Caitlin E. Cox

August 31, 2017

News Conference News ESC 2017

CANTOS: Anti-inflammatory Agent Canakinumab Modestly Reduces Major CVD Events

Michael O'Riordan

August 27, 2017

News Daily News

How Alcohol Hurts and Harms: CVD Sweet Spot Confirmed Anew in Large Meta-Analysis

Shelley Wood

August 15, 2017

News Daily News

Elevated Cardiovascular Risk May Linger for Several Years After a Severe Infection

Todd Neale

August 02, 2017

News Daily News

‘Remnant’ Cholesterol Linked With CVD Risk, Even When LDL Levels Are Low

Michael O'Riordan

August 01, 2017

News Daily News

Genetic Study Supports Link Between Serum Calcium and CAD Risk

Todd Neale

July 26, 2017

News Daily News

Staying on Statins After an Adverse Event Lowers Risks of Death, MI or Stroke

Michael O'Riordan

July 25, 2017

News Daily News

Cardiologists Issue Call to Action to Improve CVD Care for Women

L.A. McKeown

July 11, 2017

News Daily News

Cardiac Testing in Chest Pain Patients Without Ischemia Does Not Reduce Acute MI Admissions

Michael O'Riordan

June 28, 2017

News Features

Stents as Essential Medicine: India’s Cap on Stent Prices Could Have Ripples Around the Globe

Shelley Wood

May 05, 2017

News Daily News

ACC/AHA ‘Very High Risk’ Criteria Only Modestly Predict Recurrent Events

Michael O'Riordan

April 04, 2017

News Conference News ACC 2017

FOURIER: Evolocumab Reduces Risk of CVD Events by 15% Compared With Placebo

Michael O'Riordan

March 17, 2017

News Daily News

Fish Oils: Yes for HF and Secondary Prevention, No for the General Population, Says AHA

Michael O'Riordan

March 15, 2017

News Conference News ACC 2017

ACC 2017: CVD Outcomes for Evolocumab, Intermediate-Risk TAVR, Coronary Physiology Tests, and More

Shelley Wood

March 10, 2017

News Daily News

Less Acute MI, More HF: European Task Force Shifts Support for ‘Overhyped’ Cell Therapy Research

Yael L. Maxwell

February 22, 2017

Advertisement

Year in Review: Physicians Pick the Biggest News of 2017, in Interventional Cardiology and Beyond

Missed by Risk Calculators, Few Young MI Patients Were Previously on Statins

TCTMD’s Top 10 Most Popular Stories for October 2017

Lp(a) Not Associated With Adverse Cardiovascular Events in ACS Patients

Colchicine Stabilizes Plaque in ACS Patients, Imaging Study Suggests

TCTMD’s Top 10 Most Popular Stories for August 2017

CANTOS: Anti-inflammatory Agent Canakinumab Modestly Reduces Major CVD Events

How Alcohol Hurts and Harms: CVD Sweet Spot Confirmed Anew in Large Meta-Analysis

Elevated Cardiovascular Risk May Linger for Several Years After a Severe Infection

‘Remnant’ Cholesterol Linked With CVD Risk, Even When LDL Levels Are Low

Genetic Study Supports Link Between Serum Calcium and CAD Risk

Staying on Statins After an Adverse Event Lowers Risks of Death, MI or Stroke

Cardiologists Issue Call to Action to Improve CVD Care for Women

Cardiac Testing in Chest Pain Patients Without Ischemia Does Not Reduce Acute MI Admissions

Stents as Essential Medicine: India’s Cap on Stent Prices Could Have Ripples Around the Globe

ACC/AHA ‘Very High Risk’ Criteria Only Modestly Predict Recurrent Events

FOURIER: Evolocumab Reduces Risk of CVD Events by 15% Compared With Placebo

Fish Oils: Yes for HF and Secondary Prevention, No for the General Population, Says AHA

ACC 2017: CVD Outcomes for Evolocumab, Intermediate-Risk TAVR, Coronary Physiology Tests, and More

Less Acute MI, More HF: European Task Force Shifts Support for ‘Overhyped’ Cell Therapy Research

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content